Media Relations News Releases Year: - Any -2019201820172016 Items per page 102550 Apr 24, 2017 Summary ToggleNovartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS Apr 18, 2017 Summary ToggleNovartis expands development programs for NASH through clinical collaboration with Allergan Mar 21, 2017 Summary ToggleNovartis’ Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis Mar 13, 2017 Summary ToggleNovartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor Nov 29, 2016 Summary ToggleNovartis Access shares one-year learnings and announces memorandum of understanding with Rwanda Nov 14, 2016 Summary ToggleNovartis improves ranking in 2016 Access to Medicine Index Nov 14, 2016 Summary ToggleNovartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain Oct 17, 2016 Summary ToggleAlcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting Oct 3, 2016 Summary ToggleNovartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey Oct 1, 2016 Summary ToggleNovartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients Pagination First page First Previous page Previous … Page 7 Current page 8 Page 9 Page 10 … Next page Next Last page Last
